Company: SNY
Filing Date: 2025-10-27
Form Type: 424B5
Source: 0001193125-25-250786
Chunk: 29

Company: Sanofi
Filing Date: 2025-10-27
Form: 424B5
Chunk 29
---
� .                                                                              |

| (2) | None of the amounts in this table reflect significant transactions that have occurred since September 30, 
 2025.                                                                                                     |

| (3) | Since September 30, 2025, Sanofi has issued U.S. commercial paper for a total amount of $1.0 billion                                                   
 and has repaid $2.1 billion of the issued U.S. commercial paper, resulting in a net decrease of $1.1 billion of Sanofi’s outstanding commercial paper. |

S-22

USE OF PROCEEDS

The net proceeds of the offering, after deduction of underwriting discounts and commissions and expenses, amount to approximately
$ .

We intend to use the net proceeds for general corporate purposes.

S-23

DESCRIPTION OF THE NOTES

The following description of the particular terms of the notes supplements and, as applicable, supersedes the description of the general terms set forth in the attached prospectus under the heading “Description of Debt Securities We May Offer.” It is important for you to consider the information contained in this prospectus supplement and the attached prospectus before making your decision to invest in the notes. If any specific information regarding the notes in this prospectus supplement is inconsistent with the more general terms of the notes described in the attached prospectus, you should rely on the information contained in this prospectus supplement. If floating rate notes are specified in the pricing term sheet, the interest provisions will be specified therein. The below provisions apply to fixed rate notes only.

However, as indicated in the “Description of Debt Securities We May Offer,” the indenture to be entered into between us and Deutsche Bank Trust Company Americas will contain the full legal text governing the matters summarized in the referenced section “Description of Debt Securities We May Offer” of the attached prospectus and in this section, and such sections are subject to and qualified in their entirety by reference to all the provisions of the indenture. See the “Description of Debt Securities We May Offer” for more information.

General

We will offer the notes under an
indenture between the Issuer and Deutsche Bank Trust Company Americas, as trustee, to be dated as of , 2025 (the “Indenture”). The notes will be issued only in fully registered form without coupons in minimum
denominations of U.S.$2,000 and integral multiples of U.S.$1,000 in excess thereof. The notes will be unsecured and unsubordinated and therefore will rank equally with all of our other existing and future un